LCN2 targeted therapy demonstrated robust anti-tumor effects in both the in vitro 3D biomimetic chip and in vivo mouse model, including inhibition of angiogenesis, promotion of sorafenib sensitivity, and enhancement of nature killer (NK)-cell cytotoxicity (122). Here, LCN2 is linked to neoplasm.